CHIME to CMS: Hold off on Stage 3

The College of Healthcare Information Management Executives (CHIME) is urging the federal government to give healthcare providers more time to adjust to recent changes to the Meaningful Use program before mandating new and burdensome Stage 3 requirements.

The association said that extending the timeframe for Stage 3 to no sooner than 2019 would allow all stakeholders--policymakers, providers and vendors--to fully implement modifications made in October to Stage 2, and to focus energies on the critical issue of interoperability.

"CHIME members are committed to the goals of the Meaningful Use program," said CHIME Board of Trustees Chair Charles E. Christian, CHCIO, LCHIME, FCHIME. "We have made significant progress in implementing information technology systems to improve patient care and reduce costs. However, we do not believe that the course laid out by the Centers for Medicare & Medicaid Services for Stage 3 will help us achieve some important goals, including better alignment of quality improvement efforts and widespread health information exchange. We need to let providers and vendors continue down the adoption curve and perfect systems that many are still putting in place."

A “laser-like focus on interoperability” is what’s needed now, Christian said, which requires a safe, secure and accurate methodology for patient identification. More effort to protect against cyberthreats and data breaches is needed, he added.

In written comments to CMS on Stage 3 regulations published in October, CHIME made the following recommendations:

1.   Start Stage 3 no earlier than 2019 and only after 75 percent of all eligible providers have met Stage 2.

2.   Remove the 2017 transitional year for meeting Meaningful Use Stage 3 and require 2015 Edition CEHRT no earlier than 2018.

3.   Create a 90-day reporting period for every year of the program, including the first year at Stage 3, to allow providers adequate time for upgrades, planned downtime, fixes related to technology or optimizing the use of new technology within workflows.

4.   Create parity for both eligible providers and eligible hospitals by removing the existing pass/fail approach for Meaningful Use.

5.   Reduce the burden for providers by streamlining reporting redundancies and refraining from requiring data collection and submission on measures that do not advance patient care.

While CHIME “appreciates the increased flexibility CMS created in Stage 2, we are all striving to create a more efficient delivery system; one that improves patient care and lowers costs. CHIME looks forward to working with its partners in the federal government and other stakeholders as we drive towards those goals."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.